company background image
ADVM

Adverum Biotechnologies NasdaqGM:ADVM Stock Report

Last Price

US$1.18

Market Cap

US$116.5m

7D

11.3%

1Y

-66.8%

Updated

03 Jul, 2022

Data

Company Financials +
ADVM fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ADVM Stock Overview

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases.

Adverum Biotechnologies Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Adverum Biotechnologies
Historical stock prices
Current Share PriceUS$1.18
52 Week HighUS$3.66
52 Week LowUS$0.80
Beta1.29
1 Month Change28.04%
3 Month Change-9.23%
1 Year Change-66.76%
3 Year Change-90.30%
5 Year Change-53.73%
Change since IPO-95.31%

Recent News & Updates

Shareholder Returns

ADVMUS BiotechsUS Market
7D11.3%0.07%-2.5%
1Y-66.8%-25.1%-21.2%

Return vs Industry: ADVM underperformed the US Biotechs industry which returned -25.1% over the past year.

Return vs Market: ADVM underperformed the US Market which returned -21.2% over the past year.

Price Volatility

Is ADVM's price volatile compared to industry and market?
ADVM volatility
ADVM Average Weekly Movement8.8%
Biotechs Industry Average Movement13.2%
Market Average Movement8.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.3%

Stable Share Price: ADVM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ADVM's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2006188Laurent Fischerhttps://www.adverum.com

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek.

Adverum Biotechnologies Fundamentals Summary

How do Adverum Biotechnologies's earnings and revenue compare to its market cap?
ADVM fundamental statistics
Market CapUS$116.55m
Earnings (TTM)-US$155.01m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
ADVM income statement (TTM)
RevenueUS$0
Cost of RevenueUS$88.78m
Gross Profit-US$88.77m
Other ExpensesUS$66.24m
Earnings-US$155.01m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-1.57
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did ADVM perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is ADVM undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ADVM?

Other financial metrics that can be useful for relative valuation.

ADVM key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenuen/a
Enterprise Value/EBITDAn/a
PEG Ration/a

Price to Book Ratio vs Peers

How does ADVM's PB Ratio compare to its peers?

ADVM PB Ratio vs Peers
The above table shows the PB ratio for ADVM vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPBEstimated GrowthMarket Cap
Peer Average1.5x
FIXX Homology Medicines
0.4x-14.5%US$105.0m
LPTX Leap Therapeutics
1x-3.5%US$103.3m
MRZM Marizyme
2.5xn/aUS$111.5m
DTIL Precision BioSciences
2.2x41.6%US$150.5m
ADVM Adverum Biotechnologies
0.4x-0.1%US$116.5m

Price-To-Book vs Peers: ADVM is good value based on its Price-To-Book Ratio (0.4x) compared to the peer average (1.5x).


Price to Earnings Ratio vs Industry

How does ADVM's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Book vs Industry: ADVM is good value based on its Price-To-Book Ratio (0.4x) compared to the US Biotechs industry average (1.5x)


Price to Book Ratio vs Fair Ratio

What is ADVM's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ADVM PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ADVM's Price-To-Book Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of ADVM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate ADVM's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate ADVM's fair value for valuation analysis.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ADVM's PEG Ratio to determine if it is good value.


Discover undervalued companies

Future Growth

How is Adverum Biotechnologies forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


-0.1%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ADVM is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ADVM is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ADVM is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ADVM is forecast to have no revenue next year.

High Growth Revenue: ADVM is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ADVM's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Past Performance

How has Adverum Biotechnologies performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-18.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: ADVM is currently unprofitable.

Growing Profit Margin: ADVM is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ADVM is unprofitable, and losses have increased over the past 5 years at a rate of 18.3% per year.

Accelerating Growth: Unable to compare ADVM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ADVM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (98.2%).


Return on Equity

High ROE: ADVM has a negative Return on Equity (-54.78%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Adverum Biotechnologies's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: ADVM's short term assets ($280.1M) exceed its short term liabilities ($23.2M).

Long Term Liabilities: ADVM's short term assets ($280.1M) exceed its long term liabilities ($101.2M).


Debt to Equity History and Analysis

Debt Level: ADVM is debt free.

Reducing Debt: ADVM has no debt compared to 5 years ago when its debt to equity ratio was 0.04%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ADVM has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ADVM has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 21.7% each year.


Discover healthy companies

Dividend

What is Adverum Biotechnologies's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate ADVM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ADVM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ADVM's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ADVM's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as ADVM has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

1.0yrs

Average management tenure


CEO

Laurent Fischer (58 yo)

2.08yrs

Tenure

US$8,996,489

Compensation

Dr. Laurent Fischer, M.D., served as a Senior Advisor of Frazier Management, L.L.C. since March 2017 till May 2022. He joined the firm in March 2017. He was on the Frazier Life Sciences team and has severa...


CEO Compensation Analysis

Compensation vs Market: Laurent's total compensation ($USD9.00M) is above average for companies of similar size in the US market ($USD800.58K).

Compensation vs Earnings: Laurent's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: ADVM's management team is not considered experienced ( 1 years average tenure), which suggests a new team.


Board Members

Experienced Board: ADVM's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: ADVM insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Adverum Biotechnologies, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Adverum Biotechnologies, Inc.
  • Ticker: ADVM
  • Exchange: NasdaqGM
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$116.549m
  • Shares outstanding: 98.77m
  • Website: https://www.adverum.com

Number of Employees


Location

  • Adverum Biotechnologies, Inc.
  • 800 Saginaw Drive
  • Redwood City
  • California
  • 94063
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/07/03 00:00
End of Day Share Price2022/07/01 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.